Search Results

You are looking at 301 - 310 of 1,416 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Yixing Jiang, Heath Mackley, Hua Cheng, and Jaffer A. Ajani

Characteristics Among the Major Phase III Studies Ajani et al. 31 showed that patients with tumors greater than 5 cm, irregardless of nodal status, had a higher colostomy rate and inferior disease-free survival. Roohipour et al. 32 showed that treatment

Full access

Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy

. All the statistical tests were performed at a 0.05 level of significance. All statistical analyses were performed in SPSS Statistics, version 26 (IBM Corp). Results Participant Characteristics The cohort comprised 233 patients with CRC

Full access

Amro M. Abdelrahman, Ajit H. Goenka, Roberto Alva-Ruiz, Jennifer A. Yonkus, Jennifer L. Leiting, Rondell P. Graham, Kenneth W. Merrell, Cornelius A. Thiels, Christopher L. Hallemeier, Susanne G. Warner, Michael G. Haddock, Travis E. Grotz, Nguyen H. Tran, Rory L. Smoot, Wen Wee Ma, Sean P. Cleary, Robert R. McWilliams, David M. Nagorney, Thorvardur R. Halfdanarson, Michael L. Kendrick, and Mark J. Truty

pathologic response and receiver operating characteristic (ROC) curves with area under the curve. To compare ROC curves for factors, we conducted paired-sample (ie, same patient) area under the curve statistical tests using a nonparametric assumption of

Full access

Armin Shahrokni, Bella Marie Vishnevsky, Brian Jang, Saman Sarraf, Koshy Alexander, Soo Jung Kim, Robert Downey, Anoushka Afonso, and Beatriz Korc-Grodzicki

preoperative albumin level were captured from electronic medical records. Other variables assessed preoperatively included sociodemographic characteristics (age, sex, education, marital status) and surgical characteristics (site and duration of surgery

Full access

Anuhya Kommalapati, Sri Harsha Tella, Adams Kusi Appiah, Lynette Smith, and Apar Kishor Ganti

on type of therapies received and OS based on hospital volume were analyzed from the database. Table 1. Patient and Tumor Characteristics Covariates Included The primary predictor of interest in the analysis was facility volume. Factors that

Full access

Siddhartha Yadav, Sri Harsha Tella, Anuhya Kommalapati, Kristin Mara, Kritika Prasai, Mohamed Hamdy Mady, Mohamed Hassan, Rory L. Smoot, Sean P. Cleary, Mark J. Truty, Lewis R. Roberts, and Amit Mahipal

-adenocarcinoma cases were included in the final analysis. Baseline characteristics, including patient demographics, ECOG performance status, CA 19-9 level, hematologic parameters (hemoglobin [HgB], platelet count, and WBC count), hepatic parameters, and radiographic

Full access

Aileen B. Chen, Jiangong Niu, Angel M. Cronin, Ya-Chen Tina Shih, Sharon Giordano, and Deborah Schrag

increasing costs of care, it is important to understand to what extent variation in the use of high-cost technologies and the number of treatments for palliative RT can be attributed to differences in patient and disease characteristics versus systematic

Full access

Lauren Lapointe-Shaw, Hani Abushomar, Xi-Kuan Chen, Katerina Gapanenko, Chelsea Taylor, Monika K. Krzyzanowska, and Chaim M. Bell

holidays and are listed in Table 1 . When a holiday fell on a weekend, the following Monday was defined as a weekend day until 11:59 pm. Patient and Hospital Characteristics We collected information on potential patient and hospital

Full access

Changyu Shen, Enrico G. Ferro, Huiping Xu, Daniel B. Kramer, Rushad Patell, and Dhruv S. Kazi

regulatory authorities. 11 Statistical Methods Descriptive statistics were used to summarize trial characteristics for OS and PRS endpoints separately. For a given trial endpoint, we calculated the Z value by dividing the point estimate of the HR on

Full access

Dominik J. Ose, Richard Viskochil, Andreana N. Holowatyj, Mikaela Larson, Dalton Wilson, William A. Dunson Jr, Vikrant G. Deshmukh, J. Ryan Butcher, Belinda R. Taylor, Kim Svoboda, Jennifer Leiser, Benjamin Tingey, Benjamin Haaland, David W. Wetter, Simon J. Fisher, Mia Hashibe, and Cornelia M. Ulrich

levels) 24 , 26 or clinical studies with a small number of patients and a focus on one specific cancer. For both types of studies, the lack of cancer specifics (eg, first primary cancer), timing of DM onset, and/or treatment characteristics limit the